- Nachrichtendetail
-
16.05.2024 14:18:38 - dpa-AFX: Johnson & Johnson To Acquire Proteologix For $850 Mln
NEW BRUNSWICK (dpa-AFX) - Thursday, Johnson & Johnson (JNJ) announced its
agreement to acquire Proteologix, Inc., a biotechnology company specializing in
bispecific antibodies for immune-mediated diseases.
The deal involves an $850 million cash payment, with the potential for an
additional milestone payment.
The acquisition will grant J&J access to Proteologix's bispecific antibody
programs, including PX128 targeting IL-13 and TSLP, set to enter phase 1
development for moderate to severe atopic dermatitis and asthma, as well as
PX130, a biospecific antibody targeting IL-13 and IL-22, currently in
preclinical development for moderate to severe atopic dermatitis.
The transaction is expected to be finalized in mid-year 2024.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
agreement to acquire Proteologix, Inc., a biotechnology company specializing in
bispecific antibodies for immune-mediated diseases.
The deal involves an $850 million cash payment, with the potential for an
additional milestone payment.
The acquisition will grant J&J access to Proteologix's bispecific antibody
programs, including PX128 targeting IL-13 and TSLP, set to enter phase 1
development for moderate to severe atopic dermatitis and asthma, as well as
PX130, a biospecific antibody targeting IL-13 and IL-22, currently in
preclinical development for moderate to severe atopic dermatitis.
The transaction is expected to be finalized in mid-year 2024.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
JOHNSON + JOHNSON DL 1 | 853260 | Frankfurt | 135,500 | 31.05.24 20:57:08 | +1,360 | +1,01% | 0,000 | 0,000 | 134,300 | 135,500 |
